August 01, 2006
Product news from the 08/01/06 News Brief
Product news Takeda Pharmaceuticals North America said the FDA has approved its New Drug Application for Duetact (pioglitazone HCl and glimepiride), for the treatment of type 2 diabetes. Duetact combines the diabetes medications Actos (pioglitazone HCl) and glimepiride in a single tablet. The FDA has approved the expanded indication of Abbott’s rheumatoid arthritis treatment Humira (adalimumab) for reducing signs and symptoms in patients with active ankylosing spondylitis (AS), an autoimmune disease affecting the spine and large peripheral joints that causes inflammatory back pain and stiffness and also can be associated with other inflammatory diseases of the skin, eyes and intestines.